February 9, 2026 — Leads & Copy —Niagen Bioscience, Inc. (NASDAQ: NAGE), a global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, is the headlining sponsor of the inaugural NAD for Health: Opportunities & Challenges scientific meeting.
The University of Copenhagen is hosting the meeting March 23–25, 2026, at the Royal Danish Academy of Sciences and Letters in central Copenhagen. Space is limited and registration is required.
According to Andrew Shao, PhD, Senior Vice President of Regulatory and Scientific Affairs at Niagen Bioscience, advancing NAD science requires rigorous dialogue across disciplines, clear translational standards, and alignment on meaningful outcomes.
Shao stated that Niagen Bioscience is proud to support the University of Copenhagen’s inaugural NAD for Health conference because it creates an evidence-based forum that brings researchers and clinicians together to address the real barriers to translation, such as trial design, biomarkers, and regulatory considerations, so the field can move forward responsibly.
This international scientific meeting focuses on NAD metabolism and its implications for human health, one of the most rapidly advancing areas in aging and metabolic research. The conference is designed for an interdisciplinary audience of researchers, translational scientists, clinicians, and industry partners and will bring together thought leaders from world-renowned institutions.
The program includes thematic sessions, a panel discussion, and a dedicated poster session featuring short presentations from early-career researchers. The panel discussion will be livestreamed globally to broaden access to the latest advances in NAD biology and therapeutic potential. Details on the panel discussion livestream will be announced closer to the conference on the meeting website.
The meeting is being organized by Jonas Treebak, PhD, Associate Professor at the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen, and Vilhelm (Will) Bohr, MD, PhD, Affiliate Professor in Genome Instability and Neurodegeneration, also at the University of Copenhagen, in collaboration with an international organizing committee.
Drs. Bohr and Treebak previously conducted independent research on Niagen Bioscience’s patented nicotinamide riboside (NR) ingredient, Niagen, through the company’s external research program, and Dr. Bohr serves on the Scientific Advisory Board.
Dr. Treebak said the meeting was designed to convene the people generating the most important new insights in NAD biology and to do it in a setting that encourages candid, evidence-based discussion. He added that by bringing together basic, translational, and clinical perspectives, knowledge gaps can be identified, and collaborative progress toward clinical translation can be accelerated.
Key scientific themes include:
- NAD+ precursor strategies for rare orphan diseases, including Ataxia Telangiectasia (AT)
- Targeted interventions to improve healthspan and delay age-related decline
- Circulation, tissues, and organ crosstalk in response to NAD+ precursor supplementation
- NAD-boosting strategies for neurodegenerative diseases
- Translational frameworks for clinical trials and dialogue between researchers and practitioners
Dr. Bohr stated that NAD+ is central to metabolism, mitochondrial functions, DNA repair, cellular resilience, and aging biology, and the field is advancing rapidly. He added that the conference emphasizes both opportunities and limitations so that the standards, resources, and cross-sector collaboration needed to translate NAD research into meaningful health outcomes can be aligned.
Those interested in attending should contact Cathleen Brahms, Events Manager at Niagen Bioscience, at cathleen.brahms@niagenbio.com no later than Sunday, February 15, 2026. Attendance is subject to confirmation and cannot be guaranteed.
Learn more about Niagen Bioscience at www.niagenbioscience.com. For more information about the University of Copenhagen’s NAD for Health: Opportunities & Challenges Conference, please visit the conference website at https://eventsignup.ku.dk/nadforhealth.
Source: Niagen Bioscience
